David Cunningham

Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials

Background No definitive largescale data exists evaluating the role of pathologically defined regression changes within lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma ...

Naureen Starling , MBBS, MD;

A. Athauda ;

M. Nankivell ;

S. Pritchard ;

R. Langer ;

R. Langley ;

K. Von Loga ;

I. Chau ;

David Cunningham ;

H. Grabsch ;

06/30/2022

Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial

Introduction:More tolerable, readily available treatment options are needed for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) to induce deep, durable responses. ...

Michael Roost Clausen ;

Mariana Sacchi ;

Catherine Thieblemont ;

Martin Hutchings ;

Tycel Phillips ;

Pieternella Lugtenburg ;

Herve Ghesquieres ;

Chan Y. Cheah ;

Young R. Do ;

Tatyana Feldman ;

Robin Gasiorowski ;

Wojciech Jurczak ;

Tae Min Kim ;

David J. Lewis ;

Mariolein van der Poe ;

Michelle L. Poon ;

Thomas Doerr ;

Nurgul Kilavuz ;

David Cunningham ;

Menghui Chen ;

11/04/2022

Selecting the optimal first-line treatment in advanced colorectal cancer: Discussion of abstracts O-022 to O-024

David Cunningham ;

07/12/2018

Locally advanced GE junction cancer - Peri-operative CT

David Cunningham ;

07/11/2018

Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma

Background The optimal neoadjuvant treatment for resectable locally advanced carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. Moreo...

Matthieu Faron ;

Maurice Cheugoua-Zanetsie ;

Pierre Thirion ;

Jayne Tierney ;

Kathryn Winter ;

Jianhua Fu ;

David Cunningham ;

Muriel Mauer ;

06/30/2022